In trading on Tuesday, shares of Catalyst Pharmaceuticals Inc (Symbol: CPRX) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $21.1648 per share.

Powered by a 700-hp Caterpillar engine, the SX-7 is capable of producing up to a 21-inch cut depth and 102-inch width. Four cutting speeds with torque to the cutter drum rated at over 500,000 ...

Revenue Growth: Catalyst Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 43.56%.

Catalyst Pharmaceuticals appoints Dr. William Andrews as Chief Medical Officer, succeeding Dr. Gary Ingenito. Quiver AI Summary Catalyst Pharmaceuticals has announced the appointment of Dr ...

About Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases.

Grammarly has raised $1 billion in non-dilutive financing from General Catalyst to expand its artificial intelligence (AI) offerings, aiming to grow into a comprehensive productivity platform, the ...

Grammarly has secured a $1 billion commitment from General Catalyst. The 16-year-old writing assistant startup will use the new funds for its sales and marketing efforts, freeing up existing ...

General Catalyst is quietly laying the groundwork to become the first VC firm to go public. Its strategy is baffling the industry.

AI is everywhere, including at Qlik Connect 2025. But Catalyst Cloud is showing that empathy and UX design may be just as critical to analytics success.

Following the last update nearly 10 years ago, Google is updating its iconic ‘G’ icon. There are no longer four solid color sections ...

Microsoft hasn’t officially unveiled these new Office icons yet, and the company might just be looking for feedback before it tweaks them and releases something different.

Crypto market regulatory clarity is the number one catalyst for industry growth, according to a survey by Coinbase and EY-Parthenon. 86% of institutional investors said they had exposure to ...